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ABSTRACT
In recent years, numerous bacterial species have developed antibiotic resistance due to the overuse 
of antibiotics in the home, health care setting, and in agriculture. Alternative methods of treatment, 
including phage therapy (PT), have been proposed as solutions to this problem. PT is showing promise 
as an alternative method of treatment against the bacteria methicillin-resistant Staphylococcus aureus 
(MRSA). MRSA is a virulent and antibiotic resistant bacterium capable of causing infections of the skin, 
respiratory system, and various other body systems. In this research proposal, we propose investigating 
the use of the Staphylococcal bacteriophage (phage) GH15 as a therapeutic agent against MRSA 
infections due to its broad host range, its lack of bacterial virulence genes, and its strong ability to lyse 
various strains of MRSA. Specifically, we propose to evaluate the tail fibre genes of GH15 contributing 
to the phage’s host range, in addition to the ability of the phage to induce antiphage humoral immune 
responses in human cells, in the interest of exploring GH15 as a therapeutic agent for use in PT, 
specifically against MRSA.
Ces dernières années, de nombreuses espèces bactériennes ont développé une résistance aux antibiotiques en  
raison de l’usage excessif des antibiotiques à la maison, dans les établissements de soins de santé et dans l’agriculture. 
Des méthodes alternatives de traitement, y compris la thérapie par phages (TP), ont été proposées comme solutions à 
ce problème. La PT est prometteuse en tant que méthode alternative de traitement contre la bactérie Staphylococcus 
aureus résistante à la méthicilline (SARM). Le SARM est une bactérie virulente et résistante aux antibiotiques capable 
de provoquer des infections de la peau, du système respiratoire et de divers autres systèmes du corps. Dans cette 
proposition de recherche, nous proposons d’étudier l’utilisation du bactériophage staphylococcique (phage) GH15 
en tant qu’agent thérapeutique contre les infections à SARM en raison de sa large gamme d’hôtes, de son manque 
de gènes de virulence bactérienne et de sa forte capacité à lyser diverses souches de SARM. Plus précisément,  
nous proposons d’évaluer les gènes de la fibre caudale de GH15 contribuant à la gamme d’hôtes du phage, en plus 
de la capacité du phage à induire des réponses immunitaires humorales anti-phages dans les cellules humaines,  
dans l’intérêt d’explorer l’utilisation de GH15 comme agent thérapeutique en PT, précisément contre le SARM.
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Research Topic and Goals
Due to the appearance of antibiotic resistant 
bacterial strains, the scientific and medical 
communities have considered and experimented 
with the use of phages as a solution to the recent 
antibiotic crisis (Łusiak-Szelachowska et al., 2014;  
Pires et al., 2016; Xia et al., 2015). Phages are 
viruses that are only able to infect and lyse 
bacterial cells and subsequently have minimal 
to no impact on the surrounding human flora, 
making them ideal candidates for therapeutic 
use (Pires et al., 2016; Ross et al., 2016). Although 
phage therapy (PT), the use of phages to treat 
a bacterial infection (Pires et al., 2016; Ross et 
al., 2016), was controversial upon its discovery 
in the mid 1940s due to a lack of proper controls 
and inconsistent results reported by scientists at 
the time, new technology, and more controlled 
lab etiquette is allowing PT to be revisited and 
optimized to combat antibiotic resistant bacteria 
(Summers, 2012; Wittebole et al., 2013)
One of the most alarming and harmful antibiotic-
resistant bacterial genera, methicillin-resistant 
Staphylococcus aureus (MRSA), has captured 
the attention of the scientific community due to 
its antibiotic resistance and its virulence (Wang 
et al., 2016; Xia et al., 2015; Zhang et al., 2016). 
MRSA is a pathogenic bacterium known to not only 
cause superficial skin infections, but also other 
infections including deep skin infections and 
respiratory infections (Wang et al., 2016; Xia et al., 
2015). In 2011, the Centres for Disease Control and 
Prevention (CDC) estimated that 80,461 MRSA 
infections and 11,285 related deaths occurred in 
the United States. In 2013, the CDC placed MRSA 
under threat level “serious” (U.S. Department of 
Health and Human Services, 2013). Consequently, 
discovering phages that can be used to treat 
MRSA infections is of utmost importance as 
traditional antibiotic treatment methods are 
becoming ineffective (Verstappen et al., 2016; 
Wang et al., 2016).
The purpose of this research is to study the 
Staphylococcal phage GH15 and evaluate its 
potential as a therapeutic agent for the treatment 
of infections caused by MRSA. Previous studies 
have identified GH15 as a viable therapeutic 
agent due to its broad target range of S. aureus 
strains, and low host response in mammalian  
cell lines (Gu et al., 2012; Gu et al., 2013; Zhang et 
al., 2016). In this proposal, we present the idea of 
studying the tail fibre genes of GH15 responsible 
for cell attachment and host range in addition 
to monitoring the immune responses initiated 
by the human immune system against GH15 in 
order to determine the potential for GH15 as a 
therapeutic agent in humans. In this proposal, 
GH15 has been selected for study as its lack of 
bacterial virulence genes, its broad host range, 
and, additionally, its lytic ability make it an ideal 
candidate for the treatment of MRSA infections 
via PT (Gu et al., 2012; Gu et al., 2013).
Hypothesis and Questions
Due to the need for an alternative to antibiotic 
treatments, the purpose of this proposal is 
to evaluate GH15 and its application to PT. 
Specifically, two objectives are proposed to 
determine the efficacy of GH15 in PT. Aim #1 
proposes to identify which, of the seven genes 
encoding for tail fibre proteins of GH15, are 
responsible and have the largest impact on 
the host specificity of GH15. Aim #2 proposes 
to examine the safety and efficacy of GH15 
in human cells by monitoring the anti-phage 
immune response by measuring cytokine 
production (ELISA) and cell death (cytotoxicity 
assays) in A549 lung epithelial cells.
Understanding how the human immune system 
responds and reacts to the presence of phages is 
key to evaluating GH15’s potential as a therapeutic 
agent. We have chosen to monitor the levels of 
the cytokines IL-1, IL-6, TNFa, IL-4, IL-10 and the 
monocyte chemoattractant protein-1 (MCP-1 
also known as CCL-2), which all play roles in 
inflammation, produced in human cells exposed 
to GH15 using ELISA assays. These cytokines 

















were selected as they are all produced in 
response to a foreign (harmful) substance in 
the body – if the body recognizes the phages 
as harmful, an increase in the production of the 
abovementioned cytokines will be observed. 
Levels of all of these cytokines should be higher  
in response to a threat (Dinarello, 2000).  
ELISAs coupled with cytotoxicity assays will  
yield great insights into the immune response  
to the phage.
The information obtained through the following 
proposed experiments will prove to be useful in 
providing information about how GH15 can be 
used to treat MRSA infections through PT. PT 
has been proposed as an alternative to the use 
of antibiotics due to its ability to avoid collateral 
damage to the surrounding human tissues and its 
overall effectiveness in killing a target bacterial 
infection (Nobrega et al., 2015; Pires et al., 2016; 
Wang et al., 2016). In spite of the various benefits 
of PT, much still remains unknown about the full 
potential of using PT to treat bacterial infections.
Rationale
Due to the overuse of antibiotics, many bacterial 
genera are developing antibiotic resistance, 
indicating that a new method of treatment is 
required to combat bacterial infections (Zaczek 
et al., 2016). Specifically, MRSA is an alarming 
bacterial species resistant to methicillin and many 
other high-class antibiotics such as gentamicin, 
erythromycin, fluoroquinolones, and ofloxacin  
(Xia et al., 2015). MRSA is responsible for morbidity 
and mortality in a variety of lethal diseases including 
necrotizing pneumonia, overwhelming sepsis, 
pneumonia, endocarditis, and osteomyelitis 
(Wang et al., 2016; Xia et al., 2015). Due to its 
virulence and its antibiotic resistance, it is evident 
that a method of treatment be developed to fight  
MRSA infections. A number of solutions have 
been proposed in order to treat MRSA infections, 
including the use of phage lysins and PT 
(Verstappen et al., 2016; Xia et al., 2015;  
Zhang et al., 2016).
In this proposal, GH15 was selected for study. 
GH15 is a member of the Myoviridae phage family, 
of which it is among the largest phages. GH15 is  
a polyvalent phage; it is capable of infecting  
and lysing a wide range of S. aureus strains, 
including MRSA (Gu et al., 2012). GH15 lacks 
bacterial virulence genes and has a broad host  
range, making it an ideal candidate for use as  
a therapeutic agent against MRSA infections  
(Gu et al., 2012; Gu et al., 2013). Two studies in  
particular have been conducted on the use of 
phage lysins as therapeutic agents (Gu et al., 
2011; Zhang et al., 2016). LysGH15, for example, 
is a lysin derived from the phage GH15. LysGH15 
is an enzyme produced by GH15 that induces 
lysis of the host bacterial cell by targeting the 
peptidoglycan layer of the cell. When added 
externally, lysins typically access and cleave  
the cell wall peptidoglycans, making them useful  
as therapeutic agents (Zhang et al., 2016).  
A previous study (Gu et al., 2011) conducted on 
LysGH15 shows that LysGH15 has a strong ability 
to kill strains of S. aureus, especially MRSA, 
both in vitro and in vivo (in mice). The authors 
of this study demonstrate that a single injection 
of LysGH15 protected mice from fatal MRSA 
infection (Gu et al., 2011). Another study (Zhang 
et al., 2016) shows that the presence of LysGH15 
did trigger the production of LysGH15-specific 
antibodies in mice, however, these antibodies did 
not block the lytic activity in vitro or the binding 
ability of LysGH15. The use of phage lysins to 
cure bacterial infections is one method under 
consideration as an alternative to antibiotics, 
however, these lysins are extremely host specific, 
suggesting that, unlike the phages used in PT, 
the host range of phage lysins cannot be altered 
as easily. This could be a major drawback to 
their use as therapeutic agents. PT, although 
still underdeveloped, allows the use of multiple 
phages (each specific to a particular bacterial 
species) in order to target multiple bacterial 
genera (mixtures consisting of multiple phages 
designed for therapeutic use are referred to as 
phage cocktails) (Pires et al., 2016).


















PT is one of the most promising solutions to the 
antibiotic crisis (Górski and Weber-Dąbrowska, 
2004; Nobrega et al., 2015; Pires et al., 2016). 
Unlike other methods of treatment, such as the 
use of antibiotics, PT is highly specific to its target 
bacterial species, however, unlike phage lysins,  
it can be altered to target many bacterial species. 
PT involves the use of phages in order to combat 
bacterial infections. Despite the many benefits of 
PT, including the many simple, rapid, and low-cost 
phage production processes available, the ability 
of this treatment to avoid collateral damage to 
host tissue, and the overall effectiveness of this 
treatment, there are still many drawbacks to the 
use of phages as therapeutic agents (Nobrega  
et al., 2015; Pires et al., 2016).
The host specificity of PT is one such drawback 
as the tail fibre proteins (proteins on the tails 
of phages) of phages can only recognize a 
specific host receptor (displayed on the surface 
of the host bacterial cell), allowing the phage 
to attach to that cell (Pires et al., 2016; Takeuchi 
et al., 2016). An exact diagnostic of the bacteria 
resulting in infection is required before phages 
can be administered as one phage specific to a 
particular set of bacterial strain(s) will not work 
in the treatment of disease caused by other 
bacterial genera (Pires et al., 2016). Currently,  
the primary solution to this issue is the use of 
phage cocktails (they consist of a mixture of 
various phages all specific to individual bacterial 
genera) (Nobrega et al., 2015). Phage cocktails, 
however, are underdeveloped and more research 
is required before their clinical usage.
Additionally, phages can induce anti-phage 
immune responses when administered to humans 
(Daniel-Paul et al., 2011; Górski et al., 2012; 
Łusiak-Szelachowska et al., 2014). These immune 
responses do not always lead to the inactivation 
of phages, however, this has to be determined for 
each phage individually (Górski et al., 2012; Łusiak-
Szelachowska et al., 2014). In order for the full 
potential of PT to be uncovered, more research is 
required on phages and their applications to PT.
In order to evaluate the potential of phage GH15 
as a therapeutic agent, two aims have been 
proposed. The first aim is to determine which,  
of the seven identified tail fibre proteins in GH15, 
have the biggest impact on cell attachment and 
host range of GH15. The second aim is to simply 
observe the ability of GH15 to induce cytokine 
production in the human cell line A549.  
Through conducting experiments to study  
each of these aims we hope to add to the 
growing scientific knowledge of the phage  
GH15 and further its potential as a therapeutic 
agent in PT, specifically against MRSA.
Methodology and Materials
Specific Aim #1: Determine how the seven 
tail fibre proteins of GH15 affect the host 
specificity of GH15
In order to evaluate which genes are respon- 
sible for the tail fibre proteins in phage GH15,  
we analyzed the genome sequence of GH15 on 
the NCBI. The seven potential tail fibre protein 
genes were identified. These genes encode 
for putative proteins: the exact impact of each 
individual gene on the host range of GH15 is 
unknown. To determine this, we propose the 
deletion of each gene individually, producing 
seven different mutants of GH15 (each mutant 
has the deletion of one of the putative proteins). 
Homologous recombination would be used to 
create each of the different mutants.
Homologous recombination allows scientists to 
alter the host specificity of phages through the 
“swapping” of the tail fibre genes (Mahichi et al., 
2009; Pires et al., 2016). The desired genes of 
one phage are usually introduced into a bacterial 
cell via a plasmid, whereby they can be packed 
into progeny phages upon infection of the 
bacterial cell by a different phage (Pires et al., 
2016). The progeny phage produced will contain 
the tail fibre genes of another phage, resulting in 
an altered host-range from that of the parental 
phage. Homologous recombination can also be 
used to delete genes in phages. In a previous 

















study (Daniel-Paul et al., 2011), homologous 
recombination was used to create a mutant  
of the phage P954 where the endolysin gene of 
the phage was inactivated through insertional 
inactivation. In this study, we want to follow the 
procedure outlined by Daniel-Paul et al., 2011 
as a method to inactivate the genes encoding 
the tail fibre proteins in phage GH15. These 
mutants of GH15 produced through homologous 
recombination would then be exposed to 
MRSA strain USA300 in addition to strains of 
Bacillus subtilis, Streptococcus pneumoniae, 
and Escherichia coli in order to observe the host 
specificity of the mutant phages. Their ability to 
infect and lyse MRSA strain USA300 as well as 
the other bacterial strains will be determined by 
plaque assays.
Specific Aim #2: Examine cytokine  
production in response to GH15
To evaluate the levels of the cytokines IL-1, IL-6, 
TNFa, IL-4, IL-10 and MCP-1 produced by cells A549 
in the presence of GH15, and the mutants that have 
a desired response to USA300 created in Aim 1, 
an indirect enzyme-linked immunosorbent assay 
(ELISA) will be conducted. Monoclonal antibodies 
to the biomarker molecules will be monitored 
by using a secondary antibody conjugated to 
Horseradish peroxidase (HRP) for colorimetric 
detection. Additionally, a cytotoxicity assay will 
be conducted to detect whether GH15 induces 
human cell lysis. GH15 and mutants will  
be exposed to cell line A549 and the release  
of lactate dehydrogenase will be monitored  
to determine cell lysis. As a negative control,  
the phage T4 will be used as it is known not to 
induce high production levels of cytokines or 
induce human cell lysis (Miernikiewicz et al. 2013).
Results and Conclusions
Observing the Impact of tail fibre gene 
deletion on the host range of GH15
Since the seven putative tail fibre protein genes 
will be deleted individually in each of the mutants, 
we expect to see a decrease in the ability of the 
mutants to infect USA300. We expect that the 
deletion of some of the putative tail fibre genes 
will have a greater impact on the host specificity 
of GH15 than the deletion of others. It is predicted 
that some of the mutants will still be able to infect 
and lyse MRSA strain USA300, though with a 
limited ability, and others will not be able to 
infect USA300. Through the use of homologous 
recombination, it is also possible that one of 
the genes deleted could code for an essential 
protein in GH15. In the case of a deleted essential 
protein, the mutants would die before infection 
of the bacterial cells begins, suggesting that the 
genes encoding the essential protein cannot be 
removed from the phage. The identified genes 
could then be modified to change host specificity.
Studying the host specificity of GH15 is key in 
order to evaluate its potential as a therapeutic 
agent, as knowing which genes are responsible 
for GH15’s host range allows for their alteration. 
Changing the host range of a phage would allow 
this phage to be used to treat multiple bacterial 
infections as opposed to just one infection, 
promoting its use as a therapeutic agent.  
By observing the impact of tail fibre gene deletion 
on the host range of GH15, we hope to identify 
which genes are directly related to and have the 
largest impact on the host specificity of GH15, 
allowing further studies to be conducted to alter 
the host range of GH15. Altering the host range 
of GH15 would allow GH15 to not only be used to 
treat infections caused by all strains of MRSA, but 
also infections caused by other bacterial genera.
Monitoring levels of Cytokines Produced  
in Response to GH15
Through the ELISA and the cytotoxicity assays we 
will be able to determine the levels of cytokines 
produced by cells A549 in the presence of GH15 
in addition to observing whether GH15 is able to 
induce lysis of the A549 cells. Upon conduction 
of the ELISA, two possible outcomes could occur. 
In each of the scenarios GH15 will induce the 
production of cytokines. Either medium-high 
levels of cytokines will be produced or low levels 
of cytokines will be produced. In the case of 
medium-high cytokine production, we will have 
to further test whether these levels of cytokines 


















will impact the ability of GH15 to infect MRSA.  
If so, GH15 will have to be modified (the protein 
coat of the phage may have to be altered) in order 
to avoid inducing immune responses. In the case 
of low cytokine production, GH15 will not be 
affected by the immune responses, which would 
further promote GH15 as a therapeutic agent. 
Additionally, we expect the cytotoxicity assays to 
prove that GH15 does not induce lysis of cells A549.
Before a phage can be used as a therapeutic agent, 
its impact on the human immune system, and its 
ability to induce an antiphage immune response 
must be evaluated. A phage associated with high 
levels of cytokine and antibody production will 
not necessarily work as well in PT as a phage that 
induces low levels of cytokines and antibodies. 
Through ELISA and cytotoxicity assays we will 
evaluate the cytokine production in the human 
cell line A549 in response to the presence of 
phage GH15. Determining the amount of cytokines 
produced in response to GH15 is an important 
factor to consider before GH15 can be used as  
a therapeutic agent.
It must also be noted that method of phage 
administration does have an impact on the 
degree of antiphage activity (Górski et al. 
2012; Hwang et al. 2015; Łusiak-Szelachowska 
et al. 2015). Previous studies have monitored 
levels of antiphage antibodies in the serum of 
patients treated with phages (Hong et al. 2016; 
Miernikiewicz et al. 2013; Zaczek et al. 2016). 
They concluded that, in addition to phage type, 
the route of phage administration also has an 
impact on the levels of antiphage antibodies.  
Our studies do not involve the use of human  
sera and so our results are a basis for studying 
the cytokine production in response to GH15. 
Further studies will have to be conducted  
to determine the exact immune responses 
initiated against GH15 in vivo.
Final Discussion  
and Comments
The Staphylococcal phage GH15 has high potential 
as a therapeutic agent against MRSA infections. 
A therapeutic phage must have the ability to lyse 
its host cell with minimal impact on the human 
flora and the presence of a broad host range 
further impacts the decision for a phage to  
be used as a therapeutic agent. Furthermore,  
the phage must lack bacterial virulence genes  
so as to avoid making a bacterial infection worse. 
Phage GH15 not only lacks virulence genes but 
has a broad host range and a strong ability to 
lyse MRSA strains in vivo. Through determining 
the impact of the tail fibre genes on the host 
range of GH15 and the monitoring of cytokine 
production in human cells in response to GH15, 
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